Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase NA 2Phase 1/2 2Phase 3 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Thymalfasin × Clear all
NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

SciClone Pharmaceuticals

Phase 1/2 Unknown
188 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00580450 2007-12-24

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

University Of Perugia

Phase 1/2 Unknown
9 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡